Montreal, Canada, March 3, 2016 – Moleculomics, a UK university spin-out company offering powerful high-throughput prediction of small molecule – protein interactions using cutting-edge in silico modelling and screening tools, is pleased to announce the official opening of its North American sales and support office within the NEOMED Institute in Laval, Quebec.
“As an organization established for the purpose of developing new therapeutics, the NEOMED Institute offers an ideal home for our North American office,” said Dr. Will Krawszik, Head of Operations at Moleculomics. “We are pleased to be in such good company and look forward to providing services to our clients both in and around Montreal, and beyond to local life sciences hubs in Toronto and Boston,” added Dr. Jonathan Mullins, Founder and CEO.
Moleculomics Canada has been established to provide an increased level of sales and support for services developed by the UK parent company, and also seeks to develop its own intellectual property through commercializing a series of products and services, for which it has already established some strategic partnerships. The company is currently expanding and developing a Canadian-based research and development office to complement the existing UK R&D team. The first Canadian-developed product is planned for the summer of 2016 – more details will be released soon.
Pierre-Yves Desbiens, NEOMED Institute’s Vice President, Finance and Operations, commented, “We are thrilled to welcome the Moleculomics team to our hub in Laval, demonstrating that the NEOMED Institute is attracting companies as far as Europe to expand and establish headquarters in Canada. The unique technologies offered by Moleculomics in open-ended lead discovery, toxicity screening, and protein network identification across multiple genomes will benefit the life sciences ecosystem in Quebec and across North America.”
Moleculomics provides high-performance computing biosimulation tools, data resources and platforms focused on system-wide prediction of molecular interactions for the purpose of whole proteome / diverse chemistry in silico lead discovery and pathway analysis, evaluating whole system compound efficacy and toxicity.
The information is of high value to scientific and commercial decisions involved in the development and appropriation of new and existing compounds, by providing the ability to identify and prioritize efficacious leads whilst simultaneously identifying toxic or adverse reactions early in the R&D cycle.
To learn more, please visit our website: www.moleculomics.com.
ABOUT THE NEOMED INSTITUTE
The NEOMED Institute is a not-for-profit organization whose mission is to create a bridge between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with funding and a favourable ecosystem, to transform innovations into solid therapeutic solutions. NEOMED drives drug discovery activities up to the stage of human proof of concept.
The NEOMED Institute has two fully integrated research and development facilities: one in Technoparc Montréal’s Saint-Laurent Campus, specializing in small molecule therapeutics, and the other facility, specializing in the development of biologics and vaccines, in Laval. Both facilities function as open-access drug discovery hubs housing independent commercial businesses and providing a dynamic environment that stimulates collaboration, innovation, and creativity.
The NEOMED Institute is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de l’Innovation et des Exportations du Québec, and the Networks of Centres of Excellence (NCE) of Canada.
To learn more, please visit our website: www.neomed.ca.
For more information, please contact:
Head of Operations
Moleculomics In Silico Discovery Inc.
525 Boulevard Cartier Ouest
Laval, Quebec H7V 5B7
Montreal, Quebec H4S 1Z9
514-367-1212 x 209